Evotec announces potential $850m R&D partnership with Takeda

Germany’s Evotec has announced another high-profile R&D partnership with big pharma, beginning a multi-year R&D partnership with Takeda, focusing on discovering small molecule drugs

Brexit could freeze UK out of EU rare disease research, says...

The UK risks being frozen out of cutting-edge European research into rare diseases after Brexit, a patient organisation has warned.

bluebird presents long-term data from CALD gene therapy

bluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy (CALD), showing that it continues to work in the long-te

Novartis points to Zolgensma long-term benefits amid data sc...

Merck & Co in pole position for Ebola vaccine approval as FD...

The FDA is to review Merck & Co’s Ebola vaccine, giving the US pharma a chance to grab a first approval within six months.

Roche's Gazyva wins Breakthrough Therapy status for lupus ne...

Roche’s Gazyva has won Breakthrough Therapy status for its potential new use in the autoimmune disease lupus nephritis, as the Swiss pharma attempts to breathe new life into the drug curren